Journal
ENDOCRINE-RELATED CANCER
Volume 28, Issue 3, Pages R81-R93Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-20-0360
Keywords
neuroendocrine tumors; peptide receptor radionuclide therapy; PRRT; (177)Lutetium-DOTATATE; radiolabeled somatostatin analog
Categories
Funding
- [P50CA236733]
- [5K12CA90625-19]
Ask authors/readers for more resources
This review summarizes the use of radiolabeled somatostatin analogs for treating advanced NETs and emphasizes the risks and key clinical trials. Ongoing preclinical and early-phase studies are focused on the development of novel therapies for NETs.
Peptide receptor radionuclide therapy (PRRT) using Lu-177-DOTATATE has been approved for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is important for the appropriate implementation of this therapy. This review summarizes study data supporting the use of radiolabeled somatostatin analogs for the treatment of advanced NETs and highlights risks, including potential toxicities in specific populations. Key ongoing clinical trials, including randomized studies, are designed to better define the position of PRRT within the broader therapeutic landscape. Preclinical and early-phase human studies are focused on the development of novel somatostatin-receptor agonists and antagonists, new radionuclides, and radiosensitizing combination therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available